A detailed history of Rhumbline Advisers transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 79,599 shares of TNYA stock, worth $116,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,599
Previous 78,160 1.84%
Holding current value
$116,214
Previous $242,000 36.78%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.93 - $3.99 $2,777 - $5,741
1,439 Added 1.84%
79,599 $153,000
Q2 2024

Aug 01, 2024

BUY
$2.72 - $4.99 $20,239 - $37,130
7,441 Added 10.52%
78,160 $242,000
Q1 2024

May 09, 2024

BUY
$2.88 - $6.8 $6,431 - $15,184
2,233 Added 3.26%
70,719 $369,000
Q4 2023

Feb 08, 2024

BUY
$1.73 - $3.39 $823 - $1,613
476 Added 0.7%
68,486 $221,000
Q2 2023

Aug 08, 2023

BUY
$2.64 - $7.64 $8,020 - $23,210
3,038 Added 4.68%
68,010 $399,000
Q1 2023

May 11, 2023

BUY
$1.92 - $3.59 $43,217 - $80,807
22,509 Added 53.01%
64,972 $185,000
Q4 2022

Feb 14, 2023

BUY
$1.68 - $3.19 $236 - $449
141 Added 0.33%
42,463 $85,000
Q3 2022

Nov 10, 2022

BUY
$2.9 - $5.88 $6,690 - $13,565
2,307 Added 5.77%
42,322 $123,000
Q2 2022

Aug 11, 2022

BUY
$5.01 - $14.12 $86,257 - $243,104
17,217 Added 75.52%
40,015 $225,000
Q1 2022

May 12, 2022

BUY
$9.41 - $19.3 $118,998 - $244,067
12,646 Added 124.57%
22,798 $269,000
Q4 2021

Feb 10, 2022

SELL
$18.41 - $29.58 $1,288 - $2,070
-70 Reduced 0.68%
10,152 $192,000
Q3 2021

Nov 12, 2021

BUY
$15.35 - $26.66 $156,907 - $272,518
10,222 New
10,222 $211,000

Others Institutions Holding TNYA

About Tenaya Therapeutics, Inc.


  • Ticker TNYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,364,700
  • Market Cap $60.4M
  • Description
  • Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...
More about TNYA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.